GLP-1 drugs used to treat diabetes and obesity may also offer potential benefits against certain cancers.
Recent research has found a possible association between these medicines and lower cancer risks. Some studies have also examined cancer recurrence among people using GLP-1 drugs.
However, experts caution that the current evidence does not prove these medicines prevent or treat cancer.
GLP-1 Drugs Linked to Lower Cancer Risk
Medicines such as Ozempic and Wegovy have become widely used for diabetes and obesity treatment. Researchers are now examining whether these drugs could have additional health benefits.
Some studies have reported a possible link between GLP-1 drug use and lower rates of certain cancers. Research has also indicated a potentially lower likelihood of cancer returning after treatment.
However, these findings remain preliminary. Most available evidence comes from observational studies rather than controlled clinical trials.
Therefore, researchers cannot yet establish that GLP-1 drugs directly reduce cancer risk.
Research Highlights Possible Breast Cancer Connection
Dr Lauren Rourke, a breast cancer surgeon in Texas, discussed recent findings in the field.
Research presented at the 2026 American Society of Clinical Oncology (ASCO) conference indicated an association between GLP-1 drug use and lower breast cancer recurrence rates.
The findings have attracted attention because breast cancer recurrence remains an important concern following treatment.
Nevertheless, the research shows an association rather than a confirmed cause-and-effect relationship.
Experts therefore say further research is needed before drawing firm conclusions about the medicines.
Why Could GLP-1 Drugs Affect Cancer Risk?
Researchers are examining several possible explanations for the reported association.
One possibility involves weight loss linked to GLP-1 medicines. These drugs can help people lose weight, particularly when combined with appropriate lifestyle measures.
Weight loss may also reduce chronic inflammation in the body.
Another possible factor involves body fat and estrogen levels. Lower levels of excess body fat may reduce estrogen levels.
Both chronic inflammation and higher estrogen levels have been associated with the risk and outcomes of certain breast cancers.
However, these possible mechanisms do not establish that GLP-1 drugs directly prevent cancer.
More Research Needed
The emerging findings have raised interest in the potential relationship between GLP-1 drugs and cancer. At present, however, most evidence comes from observational research. Such studies can identify associations but cannot establish whether one factor directly causes another.
Therefore, researchers need stronger evidence before determining whether GLP-1 medicines could play a role in cancer prevention or recurrence.
For now, the available findings suggest a potential connection rather than a proven cancer benefit.
